Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in Waltham, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, which is an epidermal growth factor receptor (EGFR) inhibitor as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).